Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Akshaya Bio Inc., Nuron deal

March 12, 2012 7:00 AM UTC

Nuron received exclusive, worldwide rights from Akshaya to Chimigen multi-antigen vaccines to treat HBV. Nuron, which said it expects to begin a Phase I trial of the lead HBV vaccine next year, also ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article